Nvidia among investors in xAI’s $20 bln capital raise- Bloomberg
Investing.com - Oppenheimer has upgraded Boston Scientific (NYSE:BSX) from Perform to Outperform with a price target of $125.00, according to a research note released Monday. The medical device giant, currently valued at $158.87 billion, has shown impressive momentum with its stock trading near its 52-week high of $108.94.
The upgrade reflects Oppenheimer’s view that Boston Scientific represents "one of the best large-cap MedTech growth stories," driven by disciplined mergers and acquisitions and strong execution, particularly in the electrophysiology franchise. According to InvestingPro data, the company’s robust performance is evident in its 21.44% revenue growth over the last twelve months, with analysts maintaining a strong buy consensus.
Oppenheimer’s $125 price target represents approximately 52 times forward price-to-earnings ratio, compared to the aggregate large-cap MedTech space at about 30 times.
The research firm highlighted Boston Scientific’s projected 11-13% compound annual growth rate outlook as an attractive attribute for a well-diversified company, compared to approximately 8% for the aggregate large-cap MedTech sector.
Oppenheimer noted that while Boston Scientific is not immune to macro-level headwinds, the firm expects to provide additional insights and analysis following Boston Scientific’s Investor Day scheduled for September 30.
In other recent news, Boston Scientific has been experiencing a series of significant developments. The company reported a strong second quarter in 2025, with a 17% year-over-year organic revenue growth and a 23% increase in earnings per share. This performance has prompted RBC Capital to raise its price target for Boston Scientific to $125, maintaining an Outperform rating. Similarly, Truist Securities also increased their price target to $125, citing a strong quarter with positive momentum in key segments like PFA and Watchman growth. Additionally, Oppenheimer upgraded Boston Scientific’s stock rating from Perform to Outperform, highlighting the company’s effective merger and acquisition strategy.
In other updates, Boston Scientific announced the retirement of Jeffrey B. Mirviss, Executive Vice President and President of Peripheral Interventions, effective December 1, 2025. Mirviss will continue to serve as a senior advisor until February 2026. On a different note, the FDA disclosed a potentially high-risk issue with Boston Scientific’s defibrillation leads, which has been associated with patient deaths. The company has informed customers about the affected ENDOTAK RELIANCE Defibrillation leads, as part of the FDA’s initiative to enhance the Medical Device Recall Program.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.